(Information sent by the signatory company)
ROCKVILLE, Md., Dec. 14, 2022 /PRNewswire/ -- Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Ching Tian will has joined the company as chief innovation officer.
Emmes CEO, Dr. Christine Dingivan, commented: "Ching brings a wealth of digital and data expertise, which will be of immediate use as we accelerate our transition to decentralized trials. Her role is to work across the company to integrate technology and processes that will strengthen the way we will approach clinical trials of the future."
Tian stated, "As a biostatistician by training, I have spent many years running functional operations and optimizing clinical trial processes through data-centric technology. What drew me to Emmes was Dr. Dingivan's vision of Emmes as a a technology-enabled CRO, the company's roots in biostatistics, its 45-year history, and its reputation for high-quality, science-based clinical research.
"I am very proud to have contributed to the digital and decentralized clinical trials (DCT) evolution of the industry in the last five years," she said. "The speed of adoption has been unprecedented. However, solutions remain a work in progress, especially in the areas of overall complexity reduction and user experience.
"That's why this is such an exciting time for the industry and for Emmes. Our data insights and extensive experience, from design to presentation, plus our mid-size market position, will be fertile ground for innovation and scale-up quickly. I have been impressed with what the Emmes team has accomplished, and am excited to help lead the next phase of innovation," added Tian.
Prior to joining Emmes, Tian served as Senior Vice President of Strategy and Solutions at Medable, where she created and was responsible for its DCT product strategy. Her previous role was at Novartis, where she was General Manager of Data and Digitalization in global drug development, including being responsible for driving DCT strategy, programs and platforms.
In addition, Tian's CRO and pharma experience includes leadership roles at PPD and MedImmune/AstraZeneca, where he held roles of increasing responsibility in areas such as global pharmacovigilance systems, early clinical development services, global clinical informatics, data management, programming statistics and clinical technology operations.
Tian holds an MS in Biostatistics from the University of Minnesota and a BS in Industrial Engineering from Hangzhou Dianzi University of China.
"Ching knows this industry and what our clients want and need from a CRO," said Dr. Dingivan. "His experience at Medable, where he worked to ensure that technology was not built in a vacuum, but could be integrated into the business, will be invaluable in his new role at Emmes. His experience in technology, CROs, and biopharmaceutical companies is an asset. unique asset to lead the development of our Advantage eClinical platform and commercialization activities."
He added: "Ching is a visionary leader with an unmatched drive for innovation, making her the perfect fit for Emmes as we continue our strategy of accelerated global growth."
About EmmesFounded more than 45 years ago, Emmes is a global, full-service Clinical Research Organization dedicated to excellence in supporting the advancement of public health and biopharmaceutical innovation. The company's clients include numerous agencies and institutes of the US federal government and a wide range of biotechnology, pharmaceutical and medical device companies around the world. To learn more about how our research is having a positive impact on human health, visit the Emmes website at www.emmes.com.
Photo - https://mma.prnewswire.com/media/1967905...
Logo - https://mma.prnewswire.com/media/220594/...
View original content: https://www.prnewswire.com/news-releases/emmes-contrata-a-ching-tian-en-una-nueva-funcion-directiva-para-acelerar-la-innovacion-301702914.html
